Core Insights - Neurocrine Biosciences announced that its drug did not achieve the primary endpoint in a late-stage clinical trial for a disorder affecting muscle control in the brain [1] Company Summary - The drug in question was tested in patients with a specific type of disorder that disrupts the brain's ability to control muscles [1]